Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW5124 and DW5124-R pharmacokinetics and food effect study in healthy volunteers
NCT07319559Phase 1Completed
- Sponsor
- Daewon Pharm
- Start
- May 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of fexuprazan + aspirin in mixed dyslipidemia (6 arms), sponsored by Daewon Pharm. Primary endpoints: Peak Plasma Concentration at 72 hours and Area Under the Plasma Concentration Versus Time Curve at 72 hours. Started May 2025; status: completed.
02
Drugs
fexuprazan + aspirin
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT07319559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319559.